Narrow search
Showing 1 - 10 of 8,671
Cover Image
Do "reverse payment" settlements of brand-generic patent disputes in the pharmaceutical industry constitute an anticompetitive pay for delay?
Drake, Keith M.; Starr-McCluer, Martha; McGuire, Thomas G. - 2014
Persistent link: https://www.econbiz.de/10010391799
Cover Image
Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
Drake, Keith - 2014
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market...
Persistent link: https://www.econbiz.de/10013050310
Cover Image
Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
Drake, Keith M. - 2014
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market...
Persistent link: https://www.econbiz.de/10012458375
Cover Image
Stock price evidence for anticompetitive effects in the nexium "reverse-payment" settlement
Drake, Keith M.; McGuire, Thomas G. - In: Journal of competition law & economics 12 (2016) 4, pp. 735-747
Persistent link: https://www.econbiz.de/10011660496
Cover Image
The importance of financial indicators in the context of stock returns : a panel analysis on micro-determinants of stock returns : evidence from the pharmaceutical industry
Marotta, Gianfranco; Krahnhof, Philippe - In: International journal of critical accounting : IJCA 12 (2021) 6, pp. 513-530
Persistent link: https://www.econbiz.de/10013253374
Cover Image
Course technologique et valeur boursière : une étude d'événements basée sur l'industrie pharmaceutique
Campart, Sandy; Pfister, Etienne - In: Revue économique : revue bimestrielle 59 (2008) 2, pp. 307-329
Persistent link: https://www.econbiz.de/10003662956
Cover Image
Stock return outliers and beta estimation : the case of U.S. pharmaceutical companies
Theodossiou, Alexandra K.; Theodossiou, Panayiotis - In: Journal of international financial markets, … 30 (2014), pp. 153-171
Persistent link: https://www.econbiz.de/10011293772
Cover Image
Beta Estimation with Stock Return Outliers : The Case of U.S. Pharmaceutical Companies
Theodossiou, Alexandra K. - 2009
Efficient estimation of the equity cost of public corporations is an essential component of computing the required rate … verified on a sample of U.S. pharmaceutical companies by comparing the OLS estimation performance with that of our proposed … moderated but not eliminated by extending the estimation period. The latter finding suggests that a robust method like HRM is …
Persistent link: https://www.econbiz.de/10013159450
Cover Image
Risk dependence and cointegration between pharmaceutical stock markets : the case of China and the USA
Zhou, Xinmiao; Qian, Huanhuan; Pérez Rodríguez, Jorge V. - In: The North American journal of economics and finance : a … 52 (2020), pp. 1-19
Persistent link: https://www.econbiz.de/10012654918
Cover Image
The information content of management disclosures on going concern : an industry level analysis of bankruptcy prediction and investor reaction
Visvanathan, Gnanakumar - In: Journal of managerial issues : JMI 33 (2021) 4, pp. 396-419
Persistent link: https://www.econbiz.de/10012792359